ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients.

Daoud, Ahmed; Ali, Hatem; Rao, Vinaya; Rohan, Vinayak; Soliman, Karim

Daoud, Ahmed; Ali, Hatem; Rao, Vinaya; Rohan, Vinayak; Soliman, Karim.

Daoud A; Department of Internal Medicine, Cairo University Kasr Alainy Faculty of Medicine, Cairo, Egypt.
Ali H; Department of Internal Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Internal Medicine, Coventry, United Kingdom of Great Britain and Northern Ireland.
Rao V; Department of Internal Medicine, Medical University of South Carolina, Charleston, SC, USA.
Rohan V; Department of Surgery, Medical University of South Carolina, Charleston, SC, USA.
Soliman K; Department of Internal Medicine, Medical University of South Carolina, Charleston, SC, USA.

Ren Fail ; 43(1): 1463-1464, 2021 12.

Article in English | MEDLINE | ID: covidwho-1493367

Subject(s)

Angiotensin Receptor Antagonists; COVID-19; Angiotensin-Converting Enzyme Inhibitors/adverse effects; Humans; Renal Dialysis/adverse effects; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin Receptor Antagonists / COVID-19 Limits: Humans Language: English Journal: Ren Fail Journal subject: Nephrology Year: 2021 Document Type: Article Affiliation country: 0886022x.2021.1994419

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google